Phath­om Phar­ma­ceu­ti­cals re­sub­mits NDA for acid block­er, bags $130M+ from of­fer­ing

Phath­om Phar­ma­ceu­ti­cals is mak­ing an­oth­er run at get­ting a green light to add two new in­di­ca­tions for its drug vono­prazan while pric­ing a pub­lic of­fer­ing to bring in $130.7 mil­lion, the com­pa­ny an­nounced to­day.

In Feb­ru­ary, the FDA sent the com­pa­ny com­plete re­sponse let­ters for its ero­sive esophagi­tis NDA and H. py­lori post-ap­proval sup­ple­ment to “ad­dress spec­i­fi­ca­tions and con­trols for a ni­trosamine drug sub­stance re­lat­ed im­pu­ri­ty, N-ni­troso-vono­prazan.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER